BGNE - ベイジ―ン （BeiGene Ltd.） ベイジ―ンBGNEのチャート
BGNEの企業情報
| symbol | BGNE |
|---|---|
| 会社名 | BeiGene Ltd （ベイジ―ン） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ベイジーン(BeiGene Ltd.)は主にバイオ医薬品事業に従事する中国を拠点とする企業である。同社は主に、がんの治療用の革新的分子標的薬および免疫腫瘍薬の研究開発、製造および販売に従事する。同社の主要製品には、ザヌブチニブ（BGB-3111）、チーズリズマブ（BGB-A317）、パミパリブ（BGB-290）がある。 ベイジ―ンはケイマン諸島籍のバイオ医薬品企業。臨床ステ―ジで、主にがん免疫療法の開発に従事。分子標的の抗がん剤候補薬には、BTK(ブルトン型チロシンキナ―ゼ)阻害薬であるRAFタンパク質複合体と、PARP(ポリADPポリキナ―ゼ)阻害薬などを含む。オ―ストラリアとニュ―ジ―ランドで臨床実験を行い、ニュ―ジャ―ジ―州や北京などにオフィスを構える。 BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib. |
| 本社所在地 | c/o Mourant Ozannes Corporate Services (Cayman) Limited 94 Solaris Avenue Camana Bay Grand Cayman KY1-1108 CYM |
| 代表者氏名 | John V Oyler ジョンVオイラー |
| 代表者役職名 | Chairman of the Board Chief Executive Officer Founder |
| 電話番号 | +1 345-949-4123 |
| 設立年月日 | 40452 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | 900人 |
| url | www.beigene.com |
| nasdaq_url | https://www.nasdaq.com/symbol/bgne |
| adr_tso | 37297255 |
| EBITDA | EBITDA（百万ドル） -254.81800 |
| 終値（lastsale） | 146.44 |
| 時価総額（marketcap） | 5461810022.2 |
| 時価総額 | 時価総額（百万ドル） 17144.82 |
| 売上高 | 売上高（百万ドル） 323.73500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 15984.943 |
| 当期純利益 | 当期純利益（百万ドル） -240.77800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Beigene Ltd (ADR) revenues increased from $0K to $85.3M. Net loss increased from $111.2M to $261.5M. Revenues reflect Collaboration revenue increase from $0K to $30.7M. Higher net loss reflects Research and development - Balancing increase from $80.7M to $251.2M (expense) General and administrative - Balancing increase from $15.8M to $60.8M (expense). |
BGNEのテクニカル分析
BGNEのニュース
EMA panel recommends extending indication for BeiGene''s cancer drug Brukinsa 2022/09/16 13:31:51 Seeking Alpha
The European drug regulator''s human medicines committee has recommended extending the indication for BeiGene''s (BGNE) cancer drug Brukinsa
BeiGene''s Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors 2022/09/12 13:08:40 Benzinga
BeiGene Limited (NASDAQ: BGNE ) shared updates from its solid tumor development program for tislelizumab at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris. The Phase 3 RATIONALE 301 trial of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma met its primary endpoint of overall survival (OS) non-inferiority. The median OS was 15.9 … Full story available on Benzinga.com
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer 2022/09/10 06:30:00 Business Wire
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, shared updates from its solid tumor development program for cornerstone PD-1 antibody tislelizumab at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris. Results from the Phase 3 RATIONALE 301
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference 2022/09/07 23:27:00 Business Wire
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th, 2022 with a fireside chat at 9:10 a.m. ET. A live webcast
Amgen Inc. – Consensus Indicates Potential 4.4% Upside 2022/09/07 11:11:07 DirectorsTalk
Amgen Inc. found using ticker (AMGN) now have 22 analysts covering the stock. The analyst consensus points to a rating of ''Hold''. The target price ranges between 295 and 182 with a mean TP of 253.12. Given that the stocks previous close was at 242.37 this now indicates there is a potential upside of 4.4%. The 50 day moving average now sits at 246.52 and the 200 day moving average is 235.9. The market cap for the company is $129,571m. You can visit the company''s website by visiting: https://www.amgen.com [stock_market_widget type="chart" template="basic" color="green" assets="AMGN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $135,318m based on the market concensus. Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company''s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet''s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
BeiGene in pact with InnoRNA to develop messenger RNA-based therapies 2022/07/06 11:37:24 Seeking Alpha
Chinese biotechnology company, BeiGene (BGNE) announced on Wednesday an agreement to develop messenger RNA-based therapies in partnership with InnoRNA, a biotech with expertise in…
BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies 2022/07/06 11:00:00 Business Wire
BeiGene announced it entered into a worldwide strategic collaboration with InnoRNA to develop mRNA-based therapeutics.
Novartis, BeiGene tislelizumab improves survival of esophageal cancer patients in trial 2022/06/30 10:54:31 Seeking Alpha
Novartis (NVS) and BeiGene (BGNE) said tislelizumab plus chemotherapy helped improve overall ((OS)) survival in certain patients with esophageal cancer in a late-stage study.Data from…
New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy 2022/06/30 08:00:00 GlobeNewswire
Basel, June 30, 2022 — Today Novartis announced results from the Phase III RATIONALE 306 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) as a first-line treatment for adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 status. Tislelizumab plus chemotherapy demonstrated a median OS of 17.2 months (CI, 15.8-20.1 months) versus 10.6 months (CI, 9.3-12.1 months) in patients receiving chemotherapy plus placebo and reduced the risk of death by 34% (hazard ratio=0.66; CI, 0.54-0.80, p<0.0001). 1 In collaboration with BeiGene, these data were presented today during a late-breaking oral session at the 2022 European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer (Abstract #LBA-1).
Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma 2022/06/27 00:30:00 PR Newswire Asia (English)
- Selinexor is an oral small molecule XPO1 inhibitor ; tislelizumab is an anti-PD-1 checkpoint inhibitor SHANGHAI and HONG KONG , June 27, 2022 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene''s anti-PD-1 checkpoint inhibitor, tislelizumab. This multi-center, open-label Phase I/II trial will evaluate the investigational combination as a potential treatment option for patients with T and NK-cell lymphoma . "We are delighted to partner with BeiGene, a company that strives for innovation and excellence, and is committed to developing best-in-class or first-in-class anti-cancer therapies for patients across the globe.
BeiGene GAAP EPADS of -$4.24 beats by $1.08, revenue of $306.63M beats by $6.22M 2022/05/05 12:41:57 Seeking Alpha
BeiGene press release (BGNE): Q1 GAAP EPADS of -$4.24 beats by $1.08.Revenue of $306.63M (-49.4% Y/Y) beats by $6.22M.
BeiGene Reports First Quarter 2022 Financial Results 2022/05/05 11:00:00 Business Wire
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported financial results for the first quarter of 2022, recent business highlights, and anticipated upcoming milestones. “I have never been more confident in BeiGene. We made terrific progress in the first quarter with our global commercial performance in the U.S.
Amgen, BeiGene''s Blincyto gets conditional approval in China to treat blood cancer subtype in children 2022/05/04 10:30:30 Seeking Alpha
China''s National Medical Products Administration ((NMPA)) granted conditional approval to BeiGene (BGNE) and Amgen''s (AMGN) Blincyto injection to treat children with relapsed or…
BeiGene Announces the Approval in China of BLINCYTO (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL) 2022/05/04 09:53:00 Wallstreet:Online
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administration (NMPA) has granted conditional approval of BLINCYTO (blinatumomab) for injection for the treatment of pediatric